Company profile · free preview

Lexeo Therapeutics, Inc. Common Stock

LXEO · NASDAQ · Healthcare · Updated 11/16/2026

Revenue

—

Fiscal 2025

Net income

(100.0M)

Fiscal 2025

Free cash flow

(99.0M)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year202520242023
Revenue———
Net income(100.0M)(98.3M)(66.4M)
Diluted EPS———
Operating cash flow(98.6M)(81.2M)(59.5M)
Free cash flow(99.0M)(81.6M)(59.6M)
Cash$63.0M$35.0M$121.5M
Total debt———

Financial trends

Historical · FY2023–FY2025

Source: Reported annual filings (10-K / 20-F) and provider data. Fiscal years as reported; margins are calculated from the reported figures shown. Years without a reported value are left blank, not estimated.

Want the story behind these numbers? Ask Osiris anything about Lexeo Therapeutics, Inc. Common Stock's filings — free.

Create free account

Where the cash went

Cumulative, fiscal 2023–2025, straight from the reported cash-flow statements.

Reinvested in capex

—

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2023–2025

Capital expenditure $993000Bar width = share of $993000 (spending exceeded operating cash flow)
Operating cash flow($239.2M)
Capital expenditure($993000)
Free cash flow($240.2M)
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

Lexeo Therapeutics, Inc. Common Stock return on capital (fiscal 2025)

ROIC

—

Return on capital

—

Return on equity

-55.0%

Return on assets

-48.1%

Gross margin

—

Operating margin

—

Net debt / EBITDA

0.59x

Lexeo Therapeutics, Inc. Common Stock insider buying and selling

Recent open-market trades reported on Form 4. Context only — not a reason to buy or sell.

DateInsiderTypeSharesPrice
2026-08-18Tamayo Louis EdwardSale4,117$4.91
2026-08-18Otero Jose ManuelSale1,304$4.96
2026-08-18Townsend Richard NolanSale3,345$4.95
2026-07-01Bhalla Narinder PalSale22,306$4.42
2026-07-01Tamayo Louis EdwardSale4,641$4.49

SEC filings

No filings stored yet.

Ask anything about Lexeo Therapeutics, Inc. Common Stock's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

Compare LXEO head-to-head

More Healthcare companies